Industry experts agree that patient centricity should be overriding aim of global life science R&D and healthcare ecosystems.
Members of the Pistoia Alliance, a global not-for-profit that advocates for greater collaboration in life sciences R&D, have called for the life science and healthcare industries urgently to restructure around patient centricity.
More than 150 attendees meeting at the Pistoia Alliance’s annual European conference in London agreed that the sector is undergoing a significant shift. In the wake of the global pandemic and driven by continual advances in technology, the voice of the empowered patient is on the rise. The Pistoia Alliance is now calling for greater collaboration between links in the biopharmaceutical value chain to support and advance this shift and ensure that patient centricity is embedded right from early discovery to healthcare delivery.
Read more about this announcement from the Pistoia Alliance here.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.